Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts
Clearmind Medicine Inc. (NASDAQ: CMND) announces a live webinar titled "Gazing Through the Crystal Ball" scheduled for May 21, 2025, at 12:00 PM ET. The event will feature prominent experts in psychedelic science discussing the evolving landscape of the industry amid changing FDA policies and political climates.
The distinguished panel includes Rick Doblin, Founder and President of MAPS, Robin Carhart-Harris, neuropharmacologist at UCSF, Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine leading the development of CMND-100 for Alcohol Use Disorder, and Mark Haden, VP Business Development at Clearmind. The discussion will be moderated by Shannon Smadella, a social entrepreneur and former MAPS Canada board member.
Clearmind Medicine Inc. (NASDAQ: CMND) annuncia un webinar dal vivo intitolato "Guardando nella Sfera di Cristallo", previsto per il 21 maggio 2025 alle 12:00 ET. L'evento vedrà la partecipazione di esperti di spicco nel campo della scienza psichedelica che discuteranno l'evoluzione del settore in un contesto di cambiamenti nelle politiche della FDA e nel clima politico.
Il prestigioso panel comprende Rick Doblin, fondatore e presidente di MAPS, Robin Carhart-Harris, neurofarmacologo presso UCSF, Dr. Adi Zuloff-Shani, CEO di Clearmind Medicine che guida lo sviluppo di CMND-100 per il Disturbo da Uso di Alcol, e Mark Haden, vicepresidente dello sviluppo commerciale di Clearmind. La discussione sarà moderata da Shannon Smadella, imprenditrice sociale ed ex membro del consiglio di MAPS Canada.
Clearmind Medicine Inc. (NASDAQ: CMND) anuncia un seminario web en vivo titulado "Mirando a través de la bola de cristal" programado para el 21 de mayo de 2025 a las 12:00 PM ET. El evento contará con destacados expertos en ciencia psicodélica que discutirán la evolución del sector en medio de cambios en las políticas de la FDA y el clima político.
El distinguido panel incluye a Rick Doblin, fundador y presidente de MAPS, Robin Carhart-Harris, neurofarmacólogo en UCSF, Dr. Adi Zuloff-Shani, CEO de Clearmind Medicine liderando el desarrollo de CMND-100 para el Trastorno por Consumo de Alcohol, y Mark Haden, vicepresidente de Desarrollo Comercial en Clearmind. La discusión será moderada por Shannon Smadella, emprendedora social y ex miembro de la junta de MAPS Canadá.
Clearmind Medicine Inc. (NASDAQ: CMND)는 2025년 5월 21일 오후 12시 ET에 예정된 "수정구슬을 통해 바라보기"라는 제목의 라이브 웨비나를 발표합니다. 이번 행사에서는 FDA 정책 변화와 정치적 환경 속에서 진화하는 사이키델릭 과학 산업에 대해 저명한 전문가들이 논의할 예정입니다.
저명한 패널로는 MAPS의 창립자 겸 회장 릭 도블린(Rick Doblin), UCSF의 신경약리학자 로빈 카트-해리스(Robin Carhart-Harris), 알코올 사용 장애 치료제 CMND-100 개발을 이끄는 Clearmind Medicine의 CEO 아디 줄로프-샤니(Dr. Adi Zuloff-Shani), 그리고 Clearmind의 사업 개발 부사장 마크 해든(Mark Haden)이 포함됩니다. 토론은 사회적 기업가이자 전 MAPS 캐나다 이사회 멤버인 섀넌 스마델라(Shannon Smadella)가 진행합니다.
Clearmind Medicine Inc. (NASDAQ : CMND) annonce un webinaire en direct intitulé « Regarder à travers la boule de cristal » prévu pour le 21 mai 2025 à 12h00 ET. L'événement réunira des experts renommés en science psychédélique pour discuter de l'évolution du secteur dans un contexte de changements des politiques de la FDA et du climat politique.
Le panel distingué comprend Rick Doblin, fondateur et président de MAPS, Robin Carhart-Harris, neuropharmacologue à l'UCSF, Dr. Adi Zuloff-Shani, PDG de Clearmind Medicine, qui dirige le développement du CMND-100 pour le trouble lié à l'usage d'alcool, ainsi que Mark Haden, vice-président du développement commercial chez Clearmind. La discussion sera modérée par Shannon Smadella, entrepreneure sociale et ancienne membre du conseil d'administration de MAPS Canada.
Clearmind Medicine Inc. (NASDAQ: CMND) kündigt ein Live-Webinar mit dem Titel „Blick in die Kristallkugel“ an, das für den 21. Mai 2025 um 12:00 Uhr ET geplant ist. Bei der Veranstaltung werden renommierte Experten der psychedelischen Wissenschaft über die sich wandelnde Branche im Kontext veränderter FDA-Richtlinien und politischer Umfelder sprechen.
Das hochkarätige Podium umfasst Rick Doblin, Gründer und Präsident von MAPS, Robin Carhart-Harris, Neuropharmakologe an der UCSF, Dr. Adi Zuloff-Shani, CEO von Clearmind Medicine, der die Entwicklung von CMND-100 für die Behandlung der Alkoholgebrauchsstörung leitet, sowie Mark Haden, Vizepräsident für Geschäftsentwicklung bei Clearmind. Die Diskussion wird moderiert von Shannon Smadella, Sozialunternehmerin und ehemalige Vorstandsmitglied von MAPS Kanada.
- None.
- None.
Vancouver, Canada, May 20, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce its upcoming live webinar titled "Gazing Through the Crystal Ball." The event is scheduled for May 21, 2025, at 12:00 PM ET (9:00 AM PT) and will feature a distinguished panel of experts discussing the evolving landscape of psychedelic science and business in the context of changing FDA policies and political climates.
For more information: https://www.clearmindmedicine.com/upcoming-events/gazing-through-the-crystal-ball
Featured Speakers Include:
Rick Doblin, PhD – Founder and President of the Multidisciplinary Association for Psychedelic Studies (MAPS). His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist.
Robin Carhart-Harris, PhD – Robin Carhart-Harris, PhD, is an esteemed neuropharmacologist, psychologist, and became the Ralph Metzner Distinguished Professor in Neurology and Psychiatry at the University of California, San Francisco in 2021. His current research program is focused on the mechanisms of action of psychedelics and psychedelic-therapy.
Dr. Adi Zuloff-Shani – Chief Executive Officer of Clearmind Medicine. Dr. Zuloff-Shani brings decades of scientific, clinical and regulatory expertise and currently leads the development of Clearmind’s innovative treatment for Alcohol Use Disorder (AUD), CMND-100, which recently advanced into FDA-approved clinical trials.
Mark Haden – VP Business Development of Clearmind. Adjunct Professor at the University of British Columbia School of Population and Public Health and former Executive Director of MAPS Canada. Mr. Haden is a leading voice in drug policy reform and has worked extensively on public health-based approaches to psychedelic regulation and integration.
The panel discussion will be moderated by Shannon Smadella, an award-winning social entrepreneur and business strategist with deep experience in psychedelic advocacy and organizational leadership. She is a former board member of MAPS Canada, spokesperson and operations director of World Psychedelics Day, and co-director of the International Psychedelics Awareness Foundation.
“We’re in a rare moment where decades of clinical insight, policy reform, and scientific progress are converging with a vibrant psychedelic industry,” says Mark Haden, Founder of MAPS Canada, and VP at Clearmind Medicine. “As legislation evolves, the future of this field will be shaped by how we align evidence, ethics, and innovation. This webinar will explore not only the policy and research landscape, but also the emerging opportunities in a sector that is adapting, maturing, and far from slowing down.”
For additional information or media inquiries, please contact Clearmind at invest@clearmindmedicine.com.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the future of the psychedelic industry and the evolution of legislation with respect to the psychedelic industry. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
When is Clearmind Medicine (CMND) hosting its psychedelic industry webinar?
Who are the key speakers at Clearmind Medicine's (CMND) upcoming webinar?
What is CMND-100 being developed for by Clearmind Medicine?
What is the main focus of Clearmind Medicine's (CMND) webinar discussion?
